Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome Under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal Antibodies

Overview

Journal Intern Med

Specialty General Medicine

Date 2022 Sep 28

PMID 36171121

Authors

Akihiro Shimizu

Izumi Shirai

Kyohei Ogawa

Akane Miura

Kotaro Haruhara

Kentaro Oshiro

Akihiko Hamaguchi

Shinya Yokote

Masahiro Okabe

Hiroyuki Ueda

Nobuo Tsuboi

Masato Ikeda

Takashi Yokoo

Affiliations

Soon will be listed here.

Abstract

Rituximab is an effective treatment for frequently relapsing/steroid-dependent nephrotic syndrome, but there is concern about infections caused by humoral immunodeficiency. We herein report a case of prolonged (>7 weeks) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A 24-year-old man with minimal change disease treated with rituximab developed SARS-CoV-2 infection. The clinical response to remdesivir was soon transiently abolished. Treatment with casirivimab and imdevimab (REGEN-COV) monoclonal antibodies in combination with remdesivir resulted in complete clearance of the infection. The REGEN-COV antibody cocktail may improve the outcome of SARS-CoV-2 infection in patients with humoral immunodeficiency.

Citing Articles

Clinical Efficacy of Imdevimab/Casirivimab for Persistent Omicron SARS-CoV-2 Infection in Patients with Hematological Malignancies.

Hagihara M, Hayashi H, Nakashima S, Imai Y, Nakano H, Uchida T Intern Med. 2024; 63(16):2283-2287.

PMID: 38171874 PMC: 11414357. DOI: 10.2169/internalmedicine.2900-23.

Real-World Experience of the Comparative Effectiveness and Safety of Combination Therapy with Remdesivir and Monoclonal Antibodies versus Remdesivir Alone for Patients with Mild-to-Moderate COVID-19 and Immunosuppression: A Retrospective....

Hirai J, Mori N, Sakanashi D, Ohashi W, Shibata Y, Asai N Viruses. 2023; 15(9).

PMID: 37766358 PMC: 10538070. DOI: 10.3390/v15091952.

References

. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022; 399(10325):665-676. PMC: 8830904. DOI: 10.1016/S0140-6736(22)00163-5. View

Helleberg M, Niemann C, Moestrup K, Kirk O, Lebech A, Lane C . Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy. J Infect Dis. 2020; 222(7):1103-1107. PMC: 7454684. DOI: 10.1093/infdis/jiaa446. View

Cabanero-Navalon M, Garcia-Bustos V, Ruiz-Rodriguez P, Comas I, Coscolla M, Martinez-Priego L . Persistent SARS-CoV-2 infection with repeated clinical recurrence in a patient with common variable immunodeficiency. Clin Microbiol Infect. 2021; 28(2):308-310. PMC: 8579735. DOI: 10.1016/j.cmi.2021.10.021. View

Kobayashi M, Kageyama Y, Ando T, Sakamoto J, Kimura S . All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome. Clin Exp Nephrol. 2021; 25(8):854-864. PMC: 8260412. DOI: 10.1007/s10157-021-02035-6. View

Nguyen H, Salkeld J, Agarwal S, Goodman A . Compassionate use of REGN-COV2 in the treatment of COVID-19 in a patient with impaired humoral immunity. Clin Infect Pract. 2021; 12:100089. PMC: 8373583. DOI: 10.1016/j.clinpr.2021.100089. View

Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Marasa M . Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol. 2014; 25(4):850-63. PMC: 3968490. DOI: 10.1681/ASN.2013030251. View

Arai T, Mukai S, Kazama R, Ogawa Y, Nishida K, Hatanaka K . Persistent viral shedding of severe acute respiratory syndrome coronavirus 2 after treatment with bendamustine and rituximab: A case report. J Infect Chemother. 2022; 28(6):810-813. PMC: 8801906. DOI: 10.1016/j.jiac.2022.01.014. View

Curtis J, Johnson S, Anthony D, Arasaratnam R, Baden L, Bass A . American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4. Arthritis Rheumatol. 2022; 74(5):e21-e36. PMC: 9082483. DOI: 10.1002/art.42109. View

Munyentwali H, Bouachi K, Audard V, Remy P, Lang P, Mojaat R . Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int. 2013; 83(3):511-6. DOI: 10.1038/ki.2012.444. View

10.

Malsy J, Veletzky L, Heide J, Hennigs A, Gil-Ibanez I, Stein A . Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell-Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19). Clin Infect Dis. 2020; 73(11):e4020-e4024. PMC: 7665388. DOI: 10.1093/cid/ciaa1637. View

11.

Guitard J, Hebral A, Fakhouri F, Joly D, Daugas E, Rivalan J . Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance. Nephrol Dial Transplant. 2014; 29(11):2084-91. DOI: 10.1093/ndt/gfu209. View

12.

Md Yusof M, Vital E, McElvenny D, Hensor E, Das S, Dass S . Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2019; 71(11):1812-1823. DOI: 10.1002/art.40937. View

13.

Strangfeld A, Schafer M, Gianfrancesco M, Lawson-Tovey S, Liew J, Ljung L . Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021; 80(7):930-942. PMC: 7843211. DOI: 10.1136/annrheumdis-2020-219498. View

14.

Zimmerli A, Monti M, Fenwick C, Eckerle I, Beigelman-Aubry C, Pellaton C . Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery. Front Immunol. 2021; 12:613502. PMC: 8097002. DOI: 10.3389/fimmu.2021.613502. View

15.

Iwabuchi Y, Takei T, Moriyama T, Itabashi M, Nitta K . Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment. Medicine (Baltimore). 2014; 93(29):e300. PMC: 4602588. DOI: 10.1097/MD.0000000000000300. View

16.

Deveci B, Saba R . Prolonged viral positivity induced recurrent coronavirus disease 2019 (COVID-19) pneumonia in patients receiving anti-CD20 monoclonal antibody treatment: Case reports. Medicine (Baltimore). 2021; 100(52):e28470. PMC: 8718200. DOI: 10.1097/MD.0000000000028470. View

17.

Luitel P, Vais D, Gidron A . Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report. Open Forum Infect Dis. 2021; 8(8):ofab335. PMC: 8344477. DOI: 10.1093/ofid/ofab335. View

18.

Reuken P, Stallmach A, Pletz M, Brandt C, Andreas N, Hahnfeld S . Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection. Leukemia. 2021; 35(3):920-923. PMC: 7893131. DOI: 10.1038/s41375-021-01175-8. View

19.

Eisenberg R, Jawad A, Boyer J, Maurer K, McDonald K, Luning Prak E . Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol. 2012; 33(2):388-96. PMC: 3565069. DOI: 10.1007/s10875-012-9813-x. View

20.

Langer-Gould A, Smith J, Li B . Multiple sclerosis, rituximab, and COVID-19. Ann Clin Transl Neurol. 2021; 8(4):938-943. PMC: 8045943. DOI: 10.1002/acn3.51342. View